4
Changes in Ownership
Roivant Sciences Ltd. Filed Acc 0001635088-26-000071
President & Immunovant CEO sold 200,000 shares at an average $33.16 ($6,631,268)
- President & Immunovant CEO acquired 200,000 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Venker Eric · President & Immunovant CEO
Table I: Non-derivative
3 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2026-06-24 | Exercise or conversion : show line 1 in the form 10b5-1 | +200,000 | $3.85 | $770,000 | 1,813,063 | D |
| 2026-06-24 | Sale : show line 2 in the form 10b5-1 | −153,766 | $33.05 | $5,081,966 | 1,659,297 | D |
| 2026-06-24 | Sale : show line 3 in the form 10b5-1 | −46,234 | $33.51 | $1,549,301 | 1,613,063 | D |
| Open-market sales · 200,000 sh · avg $33.16 · $6,631,268 | ||||||
Table II: Derivative
1 line| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2026-06-24 | Exercise or conversion : show line 4 in the form 10b5-1 Stock Option (Right to Buy) | −200,000 | 4,244,834 | D |
Loading xslF345X06/wk-form4_1782512028.xml…